Alterity Therapeutics Limited (ATHE)
ATHE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | ATHE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | Not reported by the screener |
| SEC CIK | 0001131343 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Australia |
Financials
No annual revenue filed since the period ending 2018-06-30.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-08-28 |
| Cash and burn | 37.3M AUD cash; operating cash flow -5.6M AUD a quarter. | Report 2026-06-30 |
| Shares outstanding | 18,125,739 (2026-06-30); 760,614,224 a year earlier; 203,324,802 three years earlier. share count fell by more than half since 2025-06-30 with no split on record, which usually means a reverse split; 1y dilution not computed; share count fell by more than half since 2023-06-30 with no split on record, which usually means a reverse split; 3y dilution not computed. | Cover page 2026-06-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers, Melbourne, Australia | PCAOB Form AP 2026-09-14 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $24K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-06-30 | Not filed | -23.4M AUD | -22.5M AUD | 37.3M AUD | No debt tags | Needs four quarters | 20-F 2026-08-28 |
| FY 2025 2025-06-30 | Not filed | -12.1M AUD | -11.5M AUD | 33.2M AUD | No debt tags | Needs four quarters | 20-F 2025-08-29 |
| FY 2024 2024-06-30 | Not filed | -19.1M AUD | -12.6M AUD | 12.6M AUD | No debt tags | Needs four quarters | 20-F 2025-08-29 |
| FY 2023 2023-06-30 | Not filed | 13.8M AUD | -20.0M AUD | 15.8M AUD | No debt tags | Needs four quarters | 20-F 2023-08-31 |
| FY 2022 2022-06-30 | Not filed | 12.8M AUD | -12.3M AUD | 34.8M AUD | No debt tags | Needs four quarters | 20-F 2023-08-31 |
| FY 2021 2021-06-30 | Not filed | 15.3M AUD | -17.3M AUD | 28.1M AUD | No debt tags | Needs four quarters | 20-F 2023-08-31 |
| FY 2020 2020-06-30 | Not filed | 13.5M AUD | -9.4M AUD | 9.2M AUD | No debt tags | Needs four quarters | 20-F 2022-08-31 |
| FY 2019 2019-06-30 | Not filed | 12.3M AUD | -14.0M AUD | 14.4M AUD | No debt tags | Needs four quarters | 20-F 2021-09-02 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in AUD.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS SUPPLEMENT | 424B5 | 2024-02-15 |
| Latest annual report FORM 20-F | 20-F | 2026-08-28 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -19.3% |
| 1 month | -31.2% |
| 3 months | -58.3% |
| Year to date | -36.4% |
| 1 year | -46.9% |
| From 52-week high | -66.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| VERU | Veru Inc. | $2.08 | -0.48% | $35.5M |
| TELO | Telomir Pharmaceuticals Inc. | $0.4810 | -1.96% | $35.4M |
| OSTX | OS Therapies Incorporated | $0.6807 | -8.63% | $35.4M |
| GRCE | Grace Therapeutics Inc. | $1.75 | -3.31% | $36.8M |
| RNTX | Rein Therapeutics Inc. | $0.4000 | -27.55% | $34.5M |
| SER | Serina Therapeutics Inc. | $1.42 | +2.16% | $37.7M |
| BMEA | Biomea Fusion Inc. | $0.5201 | -10.67% | $37.8M |
| HYPD | Hyperion DeFi Inc. | $2.47 | -4.26% | $38.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier